Center for Innovative Drug Discovery 2016 San Antonio Drug Discovery Symposium Target Discovery and Drug Development in Texas June 9th and 10th 2016 8:00 AM –5:00 PM UTSA Main Campus, University Center, Denman Ballroom UTCIDD.org Day 1 8:00 AM-8:30 AM: Continental Breakfast and Registration 8:30 AM-8:45 AM: Welcome from Symposium Co-Chairs Stanton F. McHardy, Ph.D., Co-Director, Center for Innovative Drug Discovery, Director, Max and Minnie Tomerlin Voelcker Medicinal Chemistry Core Facility, UTSA Matthew Hart, Ph.D., Director, Center for Innovative Drug Discovery High Throughput Screening Core Facility, UTHSCSA 8:45-9:00 AM: Introductory remarks Dean George Perry, Ph.D., Semmes Foundation Distinguished University Chair in Neurobiology, Dean of the College of Sciences and Professor of Biology, UTSA 9:00 AM-9:50 AM: Plenary Keynote Presentation, Chair: Stanton McHardy, Ph.D. 9:00 AM-9:50 AM: Craig Lindsley, Ph.D., William K. Warren, Jr. Chair in Medicine, Professor of Pharmacology and Chemistry, Director, Medicinal Chemistry, Vanderbilt University “ Neuroscience Drug Discovery in an Academic Environment ” 9:50 AM-10:10 AM: Coffee Break 10:10 AM-12:10 PM: Session One, Chair: Bruce Nicholson, Ph.D. Identifying and Characterizing Molecular Drug Targets 10:10 AM-10:40 AM: Michael White, Professor, Cell Biology, Associate Director, Simmons Comprehensive Cancer Center, Sherry Wigley Crow Endowed Chair in Cancer Research, Grant A. Dove Distinguished Chair for Research in Oncology UT Southwestern Medical Center “Targeting mechanistic subtypes of neoplastic disease” 10:40 AM-11:10 AM: Gaston Habets, Ph.D., Sr. Director of Assay & Research Operations, Plexxikon Inc. “From drug targets to INDs, a cycle driven by Scaffold-Based Drug Discovery” 11:10 AM-11:40 AM: Peter J. A. Davies, M.D., Ph.D., Professor & Director, Center for Translational Cancer Research, Institute of Biosciences andTechnology, Texas A&M Health Science Center, Houston & Kevin Dalby, Professor of Chemical Biology & Medicinal Chemistry , The University of Texas Austin “The Gulf Coast Consortium Combinatorial Drug Discovery Program" 11:40 AM-12:10 PM: Gregory Cuny, Ph.D., Assistant Professor of Medicinal Chemistry, Department of Pharmacological and Pharmaceutical Sciences, University of Houston “CpIMPDH: A Molecular Target for Cryptosporidiosis” Day 1 12:15 PM-1:30 PM Lunch 1:30 PM-3:00 PM: Session Two, Chair: Matthew Hart, Ph.D. Assay Development and Identifying Lead Compounds 1:30 PM-2:00 PM: Bruce Posner, Ph.D. Director, HTS/RNAi Screening Core, Professor, Biochemistry Department, U.T. Southwestern Medical Center “Identification and Characterization of Potentiators of Tissue Regeneration” 2:00 PM-2:30 PM: Stan Watowich, Ph.D., Associate Professor, Department of Biochemistry & Molecular Biology, UTMB Galveston Title “DrugDiscovery@TACC: using a supercomputer web portal to find novel inhibitors of dengue and obesity diseases” 2:30 PM-3:00 PM: Conor Caffrey, Associate Professor, Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego “Identifying hits and leads for (neglected) parasitic diseases of poverty at the CDIPD” 3:00 PM-3:30 PM: John Hart, Ph.D., Ewing Halsell/President's Council Distinguished Chair in Biochemistry, UTHSCSA “Towards inhibitors of CARDS toxin, a M. pneumoniae virulence factor involved in walking pneumonia and asthma” 3:30 PM-3:50 PM Coffee Break 3:50 PM-5:00 PM: Session Three , Chair: Stan McHardy, Ph.D. Medicinal Chemistry and Drug Discovery 3:50 PM-4:20 PM: Stephen Martin, Ph.D., M. June and J. Virgil Waggoner Regents Chair in Chemistry, Department of Chemistry, UT Austin“ Progress toward a Novel Approach to Treat Neurodegenerative Diseases” 4:20 PM-4:50 PM: Jef De Brabander, Ph.D., Julie and Louis Beecherl Jr. Chair in Medical Science, Department of Biochemistry, UT Southwestern “The First Targeted Approach Towards APC-Mutated Colon Cancer: From Discovery Biology To Pre-Clinical Efficacy” 5:00 PM-7:00 PM Wine and Cheese Social and Poster Session Day 2 8:00 AM-8:30 AM Continental Breakfast 8:30 AM-10:45 AM: Session Four, Chair: Doug Frantz, Ph.D. Developing Novel Therapeutic Approaches to Cancer 8:30 AM-9:00 AM: Phil Jones, Ph.D., Executive Director and Head of Drug Discovery, Institute for Applied Cancer Science, MD Anderson “'Institute For Applied Cancer Science, Developing the Next Generation of Oncology Agents for Targeted Patient Populations” 9:00 AM-9:30 AM: Graham Beaton, Ph.D., Vice President Medicinal Chemistry, Curtana Inc. “Cancer Stem Cell Targeted Therapeutics for the Treatment of Glioblastoma and Other Brain Cancers” 9:30 AM-9:55 AM: Rong Li, Ph.D., Professor, Department of Molecular Medicine, UTHSCSA “Targeting ER-beta Signaling as a Novel Anticancer Therapy” 9:55 AM-10:20 AM: Susan Mooberry, Ph.D., Professor, Greehey Distinguished Chair in Targeted Molecular Therapeutics, Department of Pharmacology, UTHSCSA “Drug Discovery for Triple Negative Breast Cancers” 10:20 AM-10:40 AM Coffee Break 10:40 AM-12:30 PM: Session Five, Chair: Veronica Galvan, Ph.D. Therapies in Regenerative Medicine and Brain Health 10:40 AM-11:10 AM: Bob Messing, M.D., Associate Dean for Research Development at Dell Medical School, Department of Pharmacology, UT Austin Dell Medical School “Targeting protein kinase C epsilon to develop novel therapeutics against pain and addiction” 11:10 AM-11:40 PM: Thomas Knott, Ph.D., CSO, Cytocentrics Inc. “Cellular physiology of patient derived cells as a future diagnostics” 11:40 PM-12:10 PM: George Perry, Ph.D., Semmes Foundation Distinguished University Chair in Neurobiology, Dean of the College of Sciences and Professor of Biology, UTSA Title “Oxidative stress: a therapeutic window to Alzheimer disease” 12:10 PM-12:35 PM: Luke Lairson, Assistant Professor of Chemistry, Department of Chemistry, The Scripps Research Institute, California Campus Title “Phenotype-based discovery of therapeutics, targets and mechanisms” Day 2 12:35 PM-1:45 PM Lunch 1:45 PM-3:30 PM: Session Six, Chair: Steven Saville, Ph.D. Infectious Disease 1:45 PM-2:15 PM: Rob Davey, Ph.D., Interim Chair, Scientist and Ewing Halsell Scholar, Department of Virology and Immunology, Texas Biomedical Research “High throughput compound screening at high containment: new targets for Ebolavirus therapy” 2:15 PM-2:40 PM: Jose Lopez Ribot, Ph.D., Professor, Margaret Batts Tobin Distinguished Chair, Department of Biology, UTSA “Anti-virulence approaches for antifungal drug development” 2:40 PM-3:05 PM: Phil LoVerde, Ph.D., Professor, Department of Biochemistry and Pathology, UTHSCSA “Genetic basis of drug resistance in Schistosoma, development of novel therapeutics and biomarkers for human schistosomiasis” 3:05 PM-3:30 PM: Kirsten Hanson, Ph.D., Assistant Professor, Department of Biology, UTSA “Plasmodium liver stage phenotypic profiling for antimalarial drug discovery” 3:30-3:45 PM Coffee Break 3:45-4:45 Panel Discussion Panel Facilitators: Stan McHardy Doug Frantz Panel Members: Craig Lindsley Phil Jones Jef De Brabander 5:00 Adjourn Craig Lindsley Craig W. Lindsley, Ph.D. is the Co-Director and Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and running for the role of Academic Councilor for the MEDI division. Craig graduated in 1992 from California State University, Chico with a B.S. in Chemistry, received his Ph.D. degree in Chemistry from the University of California, Santa Barbara (Lipshutz), in 1996, and pursued postdoctoral studies at Harvard University (Shair). In 2001, Craig accepted a position at Merck & Co where he pioneered, in positions of increasing responsibility, the development of allosteric ligands for Akt, mGlu5 and M1, providing critical proof-of-concept compounds that validated the mechanism of allosteric modulation and clinical candidates. In 2006, Craig accepted an Associate Professor position in Pharmacology and Chemistry at Vanderbilt University, and promoted to Full Professor in 2009. In that same year, Craig became the founding Editor-in-Chief of ACS Chemical Neuroscience and was also awarded the ASPET-Astellas Award for Translational Pharmacology. In 2013, Craig was awarded the Portoghese Lectureship from the ACS MEDI division and the Journal of Medicinal Chemistry for impact in the field of medicinal chemistry, and in 2014, received the John J. Abel Award in Pharmacology from ASPET. Craig holds over 60 issued US patents and has published over 400 manuscripts and another 140 published patent applications. Michael White Dr. White is an adjunct Professor of Cell biology at UT Southwestern Medical Center and VP and CSO of Tumor Biology at Pfizer. For the past 20 years his group has been focused on decoding oncogene mechanisms of action and identifying generalizable principles of cell regulation. His group's current primary focus is genomics guided medicine with mechanism-based therapies. Gaston Habets Positions and Employment 2016-present: Sr. Director of Assay and Research Operations, Plexxikon Inc., Berkeley, CA Project manager preclinical projects, team leader for assay and screening 2012-2016: Director, Assay and Screening, Plexxikon Inc., Berkeley, CA Team leader for in house biochemical and cell biological testing, management of outsourced preclinical efficacy studies, contributed to multiple INDs including PLX3397 and PLX4032 programs 2004-2011: Senior Scientist II, Head of Assay and Screening, Plexxikon Inc., Berkeley, CA Team leader for in house biochemical and cell biological assay